Abstract
Objective
To investigate the pharmacokinetics of S-omeprazole (esomeprazole), R-omeprazole and racemic omeprazole following single and repeated oral doses of 20 mg and 40 mg of each compound in healthy male and female subjects.
Methods
In an open, randomised, three-way, cross-over study, 12 subjects received 20 mg and another 12 subjects received 40 mg S-omeprazole, R-omeprazole and racemic omeprazole as oral solutions once daily for 5 days, separated by washout periods of at least 10 days. Blood samples were taken for analysis pre-dose and at selected time points during a 12-h period following drug administration on study day 1 and day 5. Pharmacokinetic parameters of S-omeprazole, R-omeprazole, racemic omeprazole and the two main metabolites (5-hydroxy and sulphone) were calculated using non-compartmental analysis.
Results
Following the 20-mg dose of each compound, values of the total area under the plasma concentration–time curve (AUC) were 1.52, 0.62 and 1.04 μmol h/l for S-omeprazole, R-omeprazole and racemic omeprazole, respectively, on day 1. Respectively, AUC values on day 5 were 2.84, 0.68 and 1.63 μmol h/l. Corresponding values after the 40-mg doses were 3.88, 1.39 and 2.44 μmol h/l on day 1 and 9.32, 1.80 and 5.79 μmol h/l on day 5.
Conclusion
Treatment with S-omeprazole (esomeprazole; 20 mg and 40 mg) resulted in higher AUC values than with either R-omeprazole or racemic omeprazole after both single and repeated doses due to a lower metabolic rate of S-omeprazole than R-omeprazole and, consequently, racemic omeprazole. S-Omeprazole, R-omeprazole and the racemate were well tolerated.
Similar content being viewed by others
References
AstraZeneca, Data on File
Äbelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L (2000) Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 28:96–972
Andersson T, Bredberg E, Sunzel M, Antonsson M, Weidolf L (2000) Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (RO). Gastroenterology 118(4 Pt II):A1210
Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L (2001) Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40(6):411–426
Lagerström PO, Persson BA (1984) Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 309:347–356
Andersson T (1991) Pharmacokinetics of omeprazole in man; with special reference to single and repeated administration, drug interactions and polymorphic metabolism. Thesis, Göteborg University, ISBN 91-628-0180-5
Hassan-Alin M, Andersson T, Bredberg E, Röhss K (2000) Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 56:665–670
Andersson T, Cederberg C, Heggelund A, Lundborg P (1991) The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 3:45–52
Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolisers of omeprazole. Clin Pharmacol Ther 47:79–85
Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521–530
Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37:597–604
Junghard Ola, Hassan-Alin Mohammed, Hasselgren G (2000) The effect of AUC and Cmax of esomeprazole on acid secretion and intragastric pH (abstract 331). Gastroenterology 118 (4 Pt II):A17
Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L (1983) Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. Gut 24:270–276
Lind T, Rydberg L, Kylebäck A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Röhss K (2000) Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux diseases. Aliment Pharmacol Ther 14:861–867
Hunt RH (1999) Importance of pH control in the management of GERD. Arch Intern Med 159:649–57
Acknowledgements
The authors are grateful to Dr. Ola Junghard and Emma Nauclér for the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hassan-Alin, M., Andersson, T., Niazi, M. et al. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 60, 779–784 (2005). https://doi.org/10.1007/s00228-004-0841-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-004-0841-1